Erratum: Developing PRISM: A Pragmatic Institutional Survey and Bench Marking Tool to Measure Digital Research Maturity of Cancer Centers.

Autor: Albiñana CB; IQVIA, London, United Kingdom., Pallocca M; IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy., Fenton H; IQVIA, London, United Kingdom.; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Sopwith W; IQVIA, London, United Kingdom.; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Eden CV; IQVIA, London, United Kingdom., Akre O; Karolinska Comprehensive Cancer Center, Stockholm, Sweden., Auranen A; Tays Cancer Centre, Pirkanmaa, Finland., Bocquet F; Data Factory & Analytics Department, Institut de Cancérologie de l'Ouest, Nantes-Angers, France., Borges M; IQVIA, London, United Kingdom.; Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal., Calvo E; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain., Corkett J; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Di Cosimo S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Gentili N; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Guérin J; Data Office, Institut Curie, Paris, France., Jor S; Oslo University Hospital Cancer Center, Oslo, Norway., Kazda T; Masaryk Memorial Cancer Institute, Brno, Jihomoravský, Czechia., Kolar A; Institute of Oncology Ljubljana, Ljubljana, Slovenia., Kuschel T; Charité, Universitätsmedizin Berlin, Berlin, Germany., Lostes MJ; Vall d'Hebron University Hospital, Barcelona, Spain., Paratore C; University Hospital San Luigi Gonzaga of Orbassano, Orbassano TO, Italy., Pedrazzoli P; Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia PV, Italy., Petrovic M; Sestre Milosrdnice University Hospital, Zagreb, Croatia., Raid J; Tartu University Hospital, Tartu, Tartumaa, Estonia., Roche M; Trinity St James's Cancer Institute, Dublin, Ireland., Schatz C; Biobank Innsbruck, Innsbruck, Austria., Thonnard J; Cliniques Universitaires Saint-Luc, Brussels, Belgium., Tonon G; IRCCS San Raffaele Scientific Institute, Milan, Italy., Traverso A; IRCCS San Raffaele Scientific Institute, Milan, Italy.; Maastricht Comprehensive Cancer Center, Maastricht, The Netherlands.; DIGICORE, Bruxelles, Belgium., Wolf A; University Cancer Center Frankfurt (UCT), University Hospital, Goethe University, Frankfurt, Germany., Zedan AH; Vejle Hospital, University of Southern Denmark, Vejle, Denmark., Mahon P; IQVIA, London, United Kingdom.; DIGICORE, Bruxelles, Belgium.

Publikováno v: Applied clinical informatics [Appl Clin Inform] 2024 Aug; Vol. 15 (4), pp. e1. Date of Electronic Publication: 2024 Nov 04.

Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide.

Autor: Zedan AH; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark. ahmed.zedan@rsyd.dk.; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark. ahmed.zedan@rsyd.dk., Nederby L; Department of Biochemistry and Immunology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark., Volmer LM; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark., Madsen CV; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark., Sørensen BE; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark., Hansen TF; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.

Publikováno v: Scientific reports [Sci Rep] 2023 Oct 10; Vol. 13 (1), pp. 17144. Date of Electronic Publication: 2023 Oct 10.

Identification of early stage and metastatic prostate cancer using electrochemical detection of beta-2-microglobulin in urine samples from patients.

Autor: Nasimi H; Department of Science and Environment, Roskilde University, Universitetsvej 1, 4000, Roskilde, Denmark.; Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark., Madsen JS; Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark., Zedan AH; Department of Oncology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark., Malmendal A; Department of Science and Environment, Roskilde University, Universitetsvej 1, 4000, Roskilde, Denmark., Osther PJS; Department of Urology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark., Alatraktchi FA; Department of Science and Environment, Roskilde University, Universitetsvej 1, 4000, Roskilde, Denmark. alzahraa@ruc.dk.

Publikováno v: Scientific reports [Sci Rep] 2023 Jun 30; Vol. 13 (1), pp. 10658. Date of Electronic Publication: 2023 Jun 30.

Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer.

Autor: Zedan AH; Urological Research Centre, Department of Urology, Vejle Hospital, Vejle, Denmark. ahmed.hussein.riad.zedan@rsyd.dk.; Department of Oncology, Vejle Hospital, Vejle, Denmark. ahmed.hussein.riad.zedan@rsyd.dk.; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark. ahmed.hussein.riad.zedan@rsyd.dk., Osther PJS; Urological Research Centre, Department of Urology, Vejle Hospital, Vejle, Denmark.; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark., Assenholt J; Department of Biochemistry and Clinical Immunology, Vejle Hospital, Vejle, Denmark., Madsen JS; Department of Biochemistry and Clinical Immunology, Vejle Hospital, Vejle, Denmark.; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark., Hansen TF; Department of Oncology, Vejle Hospital, Vejle, Denmark.; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.

Publikováno v: Scientific reports [Sci Rep] 2020 Jan 14; Vol. 10 (1), pp. 227. Date of Electronic Publication: 2020 Jan 14.

Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer.

Autor: Hansen TF; Department of Oncology, Vejle Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark; Danish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark. Electronic address: torben.hansen@rsyd.dk., Nederby L; Department of Clinical Immunology and Biochemistry, Vejle Hospital, Vejle, Denmark. Electronic address: line.nederby@rsyd.dk., Zedan AH; Department of Oncology, Vejle Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark. Electronic address: ahmed.hussein.riad.zedan@rsyd.dk., Mejlholm I; Department of Oncology, Vejle Hospital, Vejle, Denmark. Electronic address: inge.mejlholm@rsyd.dk., Henriksen JR; Department of Oncology, Vejle Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark. Electronic address: jon.henriksen@rsyd.dk., Steffensen KD; Department of Oncology, Vejle Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark; Danish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark. Electronic address: karina.dahl.steffensen@rsyd.dk., Thomsen CB; Department of Oncology, Vejle Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark; Danish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark. Electronic address: caroline.emilie.brenner.thomsen@rsyd.dk., Raunkilde L; Department of Oncology, Vejle Hospital, Vejle, Denmark. Electronic address: louise.raunkilde.larsen@rsyd.dk., Jensen LH; Department of Oncology, Vejle Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark; Danish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark. Electronic address: lars.henrik.jensen@rsyd.dk., Jakobsen A; Department of Oncology, Vejle Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark; Danish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark. Electronic address: anders.jakobsen@rsyd.dk.

Publikováno v: Translational oncology [Transl Oncol] 2019 Jul; Vol. 12 (7), pp. 968-972. Date of Electronic Publication: 2019 May 16.